4 Undervalued Health Care Technology Stocks for Monday, November 11
Discover the top 4 undervalued Health Care Technology stocks for Monday, November 11 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Aneeqa Nadeem
Aneeqa Nadeem
Eunice Kim
Eunice Kim
Eunice Kim
| Share Statistics | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.7 | $179.6 | 2% |
|
| Shares Out (Mil) | 0.3 | 47.9 | 2% |
|
| Institutional Ownership | 100.0% | 78.6% | 99% |
|
| Float (Mil) | 1.4 | 40.1 | 4% |
|
| Beta | 1.75 | 1.22 | 88% |
|
| Avg Daily Volume (000s) | 44 | 205 | 27% |
|
| Price Change (52-week) |
(96.3%) | 41.0% | 2% |
|
| Growth | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (25.4%) | 13.7% | 2% |
|
| Net Income (5yr) | (17.4%) | (1.0%) | 23% |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $192 | 2% |
|
| Net Income (TTM) (Mil) | ($11) | ($9) | 28% |
|
| EPS (TTM) | ($59.737) | ($0.500) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | $8 | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | ($3) | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $14 | 12% |
|
| Enterprise Value (Q1) (Mil) | $2 | $215 | 4% |
|
| Valuation | ISPC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.72 | 1.22 | 45% |
|
| P/E | na | 36.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.0 | na |
|
| Ratios | ISPC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (29.6%) | 61.6% | 3% |
|
| Net Margin | na | (29.3%) | na |
|
| ROA | (165.1%) | (21.9%) | 3% |
|
| ROE | (894.6%) | (1.4%) | 0% |
|
| Liabilities to Assets | 87.7% | 33.3% | 82% |
|
| F-Score | 2 | 4 | 7% |
|
iSpecimen Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors